236 related articles for article (PubMed ID: 11074901)
1. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial.
Beyth RJ; Quinn L; Landefeld CS
Ann Intern Med; 2000 Nov; 133(9):687-95. PubMed ID: 11074901
[TBL] [Abstract][Full Text] [Related]
2. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
3. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
5. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
6. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
Wang SV; Franklin JM; Glynn RJ; Schneeweiss S; Eddings W; Gagne JJ
BMJ; 2016 May; 353():i2607. PubMed ID: 27221664
[TBL] [Abstract][Full Text] [Related]
7. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
Arch Intern Med; 1996 Feb; 156(4):409-16. PubMed ID: 8607726
[TBL] [Abstract][Full Text] [Related]
8. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Agarwal S; Bennett D; Smith DJ
Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
[TBL] [Abstract][Full Text] [Related]
9. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
Couturaud F; Sanchez O; Pernod G; Mismetti P; Jego P; Duhamel E; Provost K; dit Sollier CB; Presles E; Castellant P; Parent F; Salaun PY; Bressollette L; Nonent M; Lorillon P; Girard P; Lacut K; Guégan M; Bosson JL; Laporte S; Leroyer C; Décousus H; Meyer G; Mottier D;
JAMA; 2015 Jul; 314(1):31-40. PubMed ID: 26151264
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
Wieloch M; Själander A; Frykman V; Rosenqvist M; Eriksson N; Svensson PJ
Eur Heart J; 2011 Sep; 32(18):2282-9. PubMed ID: 21616951
[TBL] [Abstract][Full Text] [Related]
11. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Li J; Rodríguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple BD; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Anderson JL; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
JAMA; 2017 Sep; 318(12):1115-1124. PubMed ID: 28973620
[TBL] [Abstract][Full Text] [Related]
12. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
[TBL] [Abstract][Full Text] [Related]
13. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of a novel patient self-management program for warfarin therapy using venipuncture-acquired international normalized ratio monitoring.
Simmons BJ; Jenner KM; Delate T; Clark NP; Kurz D; Witt DM
Pharmacotherapy; 2012 Dec; 32(12):1078-84. PubMed ID: 23112110
[TBL] [Abstract][Full Text] [Related]
15. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.
Kearon C; Ginsberg JS; Kovacs MJ; Anderson DR; Wells P; Julian JA; MacKinnon B; Weitz JI; Crowther MA; Dolan S; Turpie AG; Geerts W; Solymoss S; van Nguyen P; Demers C; Kahn SR; Kassis J; Rodger M; Hambleton J; Gent M;
N Engl J Med; 2003 Aug; 349(7):631-9. PubMed ID: 12917299
[TBL] [Abstract][Full Text] [Related]
16. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
Francis CW; Davidson BL; Berkowitz SD; Lotke PA; Ginsberg JS; Lieberman JR; Webster AK; Whipple JP; Peters GR; Colwell CW
Ann Intern Med; 2002 Oct; 137(8):648-55. PubMed ID: 12379064
[TBL] [Abstract][Full Text] [Related]
17. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
18. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
[TBL] [Abstract][Full Text] [Related]
19. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
[TBL] [Abstract][Full Text] [Related]
20. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
